英夫利西单抗对炎症性肠病的疗效及安全性分析  

Efficacy and safety of Infliximab on inflammatory bowel disease

作　　者：范如英[1] 盛剑秋[1] 陆晓娟[1] 李恕军[1] 王继恒[1] 杨欣艳[1] 王晓伟[1] 李世荣[1] 

机构地区：[1]北京军区总医院消化内科,北京100700

出　　处：《胃肠病学和肝病学杂志》2013年第9期898-900,共3页Chinese Journal of Gastroenterology and Hepatology

摘　　要：目的了解英夫利西单抗对炎症性肠病的疗效及安全性。方法回顾性分析北京军区总医院2007年1月-2013年1月住院的27例激素抵抗或依赖中-重度IBD患者的临床及内镜资料,分别在用药后6周、30周、54周进行Mayo或CDAI评分,总结结肠镜下黏膜改变,并记录不良反应。结果英夫利西单抗对CD患者有效率为89.5%,激素抵抗或依赖的UC患者有效率为83.0%,二者比较差异无统计学意义(P>0.05),总体有效率为84.8%,7例达到黏膜愈合。5例患者发生不良反应,包括输液反应、呼吸道感染、白细胞轻度降低。结论英夫利西单抗对CD及UC患者疗效好,不良反应轻,具有较好的临床应用价值。Objective To analyze efficacy and safety of Infliximab （IFX） on inflammatory bowel disease. Methods Twenty seven patients with inflammatory bowel disease （IBD） in our hospital from Jan. 2007 to Jan. 2013, including 19 patients with ulcerative colitis （UC） and 8 patients with Crohn＇ s disease （CD） , entered our study. The clinical and endoscopic data of the patients were collected. Mayo score for UC, Crohn＇ s disease active index （CDAI） for CD at 6, 30 and 54 weeks after injection Infliximab were conducted respectively. Adverse reaction were evaluated. Results The results showed that 89.5% CD and 83.0% UC were responded to Infliximab. Average response rate of UC and CD to Infliximab was 84.8%. There was no difference between UC and CD （P 〉 0.05 ）. Seven patients attained mucosal heal- ing. Five patients happened adverse reaction including infusion reaction, respiratory infection and neutropenia. Conclu- sion The results indicated that IBD had high response to Infliximab and light adverse reaction, Infliximab would be a better choice for IBD.

关 键 词：英夫利西单抗 炎症性肠病 疗效 不良反应 

分 类 号：R574.62[医药卫生—消化系统]